 Cristos Ifantides
Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cataract | 8 | 2023 | 185 | 3.260 |
Why?
| | Cataract Extraction | 4 | 2023 | 76 | 2.520 |
Why?
| | Lenses, Intraocular | 4 | 2022 | 42 | 1.660 |
Why?
| | Ophthalmology | 2 | 2023 | 77 | 1.590 |
Why?
| | Capsulorhexis | 2 | 2022 | 8 | 1.040 |
Why?
| | Posterior Capsulotomy | 1 | 2022 | 7 | 0.860 |
Why?
| | Lens Capsule, Crystalline | 1 | 2022 | 9 | 0.850 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 79 | 0.830 |
Why?
| | Dry Eye Syndromes | 4 | 2023 | 28 | 0.830 |
Why?
| | Lens Subluxation | 1 | 2021 | 3 | 0.750 |
Why?
| | Weapons | 1 | 2021 | 9 | 0.750 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.750 |
Why?
| | Political Activism | 1 | 2021 | 10 | 0.750 |
Why?
| | Health Status Disparities | 1 | 2023 | 204 | 0.730 |
Why?
| | Language | 1 | 2023 | 258 | 0.730 |
Why?
| | Eye Injuries | 1 | 2021 | 45 | 0.720 |
Why?
| | Granuloma, Foreign-Body | 1 | 2020 | 10 | 0.700 |
Why?
| | Tattooing | 1 | 2020 | 11 | 0.700 |
Why?
| | Hepatitis C | 1 | 2022 | 229 | 0.690 |
Why?
| | Macular Edema | 1 | 2020 | 35 | 0.670 |
Why?
| | Uveitis | 1 | 2020 | 115 | 0.640 |
Why?
| | Glaucoma, Open-Angle | 2 | 2021 | 95 | 0.620 |
Why?
| | Healthcare Disparities | 1 | 2023 | 485 | 0.590 |
Why?
| | Nocardia | 1 | 2015 | 1 | 0.510 |
Why?
| | Nocardia Infections | 1 | 2015 | 7 | 0.500 |
Why?
| | Eye Infections, Bacterial | 1 | 2015 | 26 | 0.490 |
Why?
| | Internship and Residency | 1 | 2023 | 951 | 0.450 |
Why?
| | Surgical Wound Infection | 1 | 2015 | 250 | 0.410 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 9 | 0.390 |
Why?
| | Lens Implantation, Intraocular | 2 | 2022 | 57 | 0.380 |
Why?
| | Phacoemulsification | 2 | 2023 | 107 | 0.380 |
Why?
| | Retrospective Studies | 8 | 2023 | 12608 | 0.370 |
Why?
| | Trabeculectomy | 2 | 2021 | 65 | 0.300 |
Why?
| | Humans | 22 | 2023 | 115587 | 0.260 |
Why?
| | Refraction, Ocular | 2 | 2022 | 30 | 0.240 |
Why?
| | Postoperative Complications | 4 | 2022 | 2161 | 0.220 |
Why?
| | Masks | 1 | 2023 | 46 | 0.220 |
Why?
| | Corneal Injuries | 1 | 2023 | 34 | 0.210 |
Why?
| | Anesthetics, Local | 1 | 2023 | 84 | 0.210 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2022 | 33 | 0.210 |
Why?
| | Photorefractive Keratectomy | 1 | 2022 | 13 | 0.210 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2022 | 16 | 0.210 |
Why?
| | United States | 3 | 2023 | 12295 | 0.200 |
Why?
| | Glaucoma Drainage Implants | 1 | 2022 | 47 | 0.200 |
Why?
| | Alanine Transaminase | 1 | 2022 | 141 | 0.200 |
Why?
| | Safety-net Providers | 1 | 2023 | 96 | 0.200 |
Why?
| | Visual Acuity | 2 | 2022 | 273 | 0.200 |
Why?
| | Intraoperative Complications | 1 | 2022 | 126 | 0.190 |
Why?
| | Dissent and Disputes | 1 | 2021 | 18 | 0.190 |
Why?
| | Aberrometry | 1 | 2020 | 9 | 0.190 |
Why?
| | Republic of Korea | 1 | 2020 | 27 | 0.190 |
Why?
| | Crowding | 1 | 2021 | 37 | 0.180 |
Why?
| | Hepacivirus | 1 | 2022 | 234 | 0.180 |
Why?
| | Optics and Photonics | 1 | 2020 | 43 | 0.180 |
Why?
| | Myopia | 1 | 2020 | 37 | 0.180 |
Why?
| | Foreign-Body Reaction | 1 | 2020 | 23 | 0.170 |
Why?
| | Adalimumab | 1 | 2020 | 44 | 0.170 |
Why?
| | Glaucoma | 1 | 2022 | 204 | 0.170 |
Why?
| | Benchmarking | 1 | 2020 | 163 | 0.170 |
Why?
| | Ambulatory Care | 1 | 2023 | 478 | 0.170 |
Why?
| | Education, Medical, Graduate | 1 | 2023 | 376 | 0.170 |
Why?
| | Steroids | 1 | 2020 | 147 | 0.160 |
Why?
| | Health Surveys | 1 | 2021 | 446 | 0.160 |
Why?
| | Glucocorticoids | 1 | 2022 | 552 | 0.150 |
Why?
| | Intraocular Pressure | 2 | 2022 | 277 | 0.150 |
Why?
| | Curriculum | 1 | 2023 | 852 | 0.140 |
Why?
| | Clinical Competence | 1 | 2023 | 912 | 0.140 |
Why?
| | Biopsy | 1 | 2020 | 1056 | 0.130 |
Why?
| | Surgical Stomas | 1 | 2015 | 6 | 0.130 |
Why?
| | Amikacin | 1 | 2015 | 20 | 0.120 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2015 | 39 | 0.120 |
Why?
| | Tomography, Optical Coherence | 1 | 2015 | 128 | 0.120 |
Why?
| | Cornea | 2 | 2023 | 107 | 0.100 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 962 | 0.100 |
Why?
| | Risk Factors | 2 | 2022 | 8697 | 0.100 |
Why?
| | Sports Equipment | 1 | 2011 | 6 | 0.100 |
Why?
| | Staphylococcal Skin Infections | 1 | 2011 | 29 | 0.090 |
Why?
| | Equipment Contamination | 1 | 2011 | 54 | 0.090 |
Why?
| | Receptors, CCR2 | 1 | 2009 | 28 | 0.090 |
Why?
| | Shear Strength | 1 | 2009 | 55 | 0.090 |
Why?
| | Transplants | 1 | 2009 | 37 | 0.080 |
Why?
| | Tunica Intima | 1 | 2009 | 78 | 0.080 |
Why?
| | Community-Acquired Infections | 1 | 2011 | 140 | 0.080 |
Why?
| | Veins | 1 | 2009 | 57 | 0.080 |
Why?
| | Male | 7 | 2023 | 55949 | 0.080 |
Why?
| | Prospective Studies | 1 | 2020 | 6264 | 0.080 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2011 | 192 | 0.080 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2008 | 24 | 0.080 |
Why?
| | Graft Occlusion, Vascular | 1 | 2008 | 35 | 0.080 |
Why?
| | Adult | 4 | 2023 | 30718 | 0.070 |
Why?
| | Jugular Veins | 1 | 2007 | 38 | 0.070 |
Why?
| | Immediate-Early Proteins | 1 | 2007 | 53 | 0.070 |
Why?
| | Blood Vessels | 1 | 2008 | 181 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2008 | 239 | 0.070 |
Why?
| | C-Reactive Protein | 1 | 2008 | 364 | 0.070 |
Why?
| | Prevalence | 2 | 2022 | 2264 | 0.070 |
Why?
| | Incidence | 2 | 2022 | 2335 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1484 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2007 | 350 | 0.060 |
Why?
| | Graft Survival | 1 | 2007 | 480 | 0.060 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 446 | 0.060 |
Why?
| | Tears | 1 | 2023 | 14 | 0.060 |
Why?
| | Middle Aged | 3 | 2023 | 26999 | 0.060 |
Why?
| | Meibomian Glands | 1 | 2022 | 7 | 0.050 |
Why?
| | Lubricant Eye Drops | 1 | 2022 | 4 | 0.050 |
Why?
| | Loteprednol Etabonate | 1 | 2022 | 6 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2022 | 4440 | 0.050 |
Why?
| | Tobramycin | 1 | 2022 | 48 | 0.050 |
Why?
| | Lasers, Excimer | 1 | 2022 | 21 | 0.050 |
Why?
| | Fibroblasts | 1 | 2007 | 839 | 0.050 |
Why?
| | Communication Barriers | 1 | 2023 | 90 | 0.050 |
Why?
| | Cyclosporine | 1 | 2022 | 169 | 0.050 |
Why?
| | Analgesics | 1 | 2023 | 157 | 0.050 |
Why?
| | Pain, Postoperative | 1 | 2023 | 195 | 0.050 |
Why?
| | Mitomycin | 1 | 2021 | 27 | 0.050 |
Why?
| | Prosthesis Implantation | 1 | 2022 | 139 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 161 | 0.050 |
Why?
| | Intraoperative Period | 1 | 2020 | 50 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 4435 | 0.050 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 301 | 0.050 |
Why?
| | India | 1 | 2020 | 135 | 0.050 |
Why?
| | Global Health | 1 | 2022 | 290 | 0.050 |
Why?
| | Disease Outbreaks | 1 | 2022 | 308 | 0.040 |
Why?
| | Cell Movement | 3 | 2009 | 867 | 0.040 |
Why?
| | Aged | 3 | 2023 | 19251 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2022 | 509 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 585 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2022 | 9159 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1216 | 0.040 |
Why?
| | Rabbits | 2 | 2009 | 752 | 0.040 |
Why?
| | Signal Transduction | 1 | 2009 | 4541 | 0.030 |
Why?
| | Research Design | 1 | 2021 | 946 | 0.030 |
Why?
| | Female | 4 | 2023 | 59913 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2022 | 3022 | 0.030 |
Why?
| | Adolescent | 2 | 2023 | 17889 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2020 | 805 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2020 | 6417 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2009 | 105 | 0.020 |
Why?
| | Hyperplasia | 1 | 2009 | 166 | 0.020 |
Why?
| | Child, Preschool | 1 | 2022 | 9133 | 0.020 |
Why?
| | Leukocytes | 1 | 2009 | 281 | 0.020 |
Why?
| | Young Adult | 1 | 2023 | 10470 | 0.020 |
Why?
| | Elastin | 1 | 2008 | 78 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2008 | 154 | 0.020 |
Why?
| | Gene Deletion | 1 | 2009 | 355 | 0.020 |
Why?
| | Transplantation, Autologous | 1 | 2008 | 173 | 0.020 |
Why?
| | Chemotaxis | 1 | 2008 | 132 | 0.020 |
Why?
| | Connective Tissue Growth Factor | 1 | 2007 | 21 | 0.020 |
Why?
| | Blotting, Western | 1 | 2008 | 1153 | 0.020 |
Why?
| | Hemodynamics | 1 | 2009 | 968 | 0.020 |
Why?
| | Cell Survival | 1 | 2008 | 1024 | 0.020 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2008 | 691 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 1870 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1571 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2008 | 1642 | 0.010 |
Why?
| | Child | 1 | 2022 | 18488 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2194 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 3914 | 0.010 |
Why?
| | Phenotype | 1 | 2008 | 2829 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2009 | 2353 | 0.010 |
Why?
| | Animals | 2 | 2009 | 32102 | 0.010 |
Why?
| | Mice | 1 | 2009 | 15052 | 0.010 |
Why?
|
|
Ifantides's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|